What is the effect of prolactin on a women's risk for breast cancer?

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. (SEER). Cancer stat facts: female breast cancer. Available at http://seer.cancer.gov/statfacts/html/breast.html. 2019; Accessed: December 26, 2019.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan. 69 (1):7-34. [Medline]. [Full Text].

3. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019 Nov. 69 (6):438-51. [Medline]. [Full Text].

4. Seow A, Duffy SW, McGee MA, Lee J, Lee HP. Breast cancer in Singapore: trends in incidence 1968-1992. Int J Epidemiol. 1996 Feb. 25(1):40-5. [Medline].

5. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst. 1980 Sep. 65(3):559-69. [Medline].

6. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000 Nov 15. 152(10):950-64. [Medline].

7. National Center for Health Statistics. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute; 1998.

8. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2015 Oct 29. [Medline].

9. Mulcahy N. Gap Is Gone: Breast Cancer Rates Now Equal in Blacks, Whites. Medscape Medical News. Available at http://www.medscape.com/viewarticle/853418. October 29, 2015; Accessed: December 18, 2015.

10. Stanford JL, Herrinton LJ, Schwartz SM, Weiss NS. Breast cancer incidence in Asian migrants to the United States and their descendants. Epidemiology. 1995 Mar. 6(2):181-3. [Medline].

11. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993 Nov 17. 85(22):1819-27. [Medline].

12. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006 Nov 20. 24(33):e49-50. [Medline].

13. Persson I, Bergstrom R, Barlow L, Adami HO. Recent trends in breast cancer incidence in Sweden. Br J Cancer. 1998. 77(1):167-9. [Medline].

14. Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries. BMJ. 1995 Nov 25. 311(7017):1391-5. [Medline]. [Full Text].

15. Matheson I, Tretli S. Changes in breast cancer incidence among Norwegian women under 50. Lancet. 1996 Sep 28. 348(9031):900-1. [Medline].

16. Tominaga S, Aoki K, Fujimoto I, Kurihara M. Cancer Mortality and Morbidity Statistics: Japan and the World-1994. Tokyo: Japan Scientific Societies Press; 1994.

17. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993. 15(1):48-65. [Medline].

18. Wu AH, Stanczyk FZ, Seow A, Lee HP, Yu MC. Soy intake and other lifestyle determinants of serum estrogen levels among postmenopausal Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev. 2002 Sep. 11(9):844-51. [Medline].

19. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994 Apr 15. 139(8):819-35. [Medline].

20. Rosner B, Colditz GA. Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst. 1996 Mar 20. 88(6):359-64. [Medline].

21. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. 2003 Dec. 160(6):707-17. [Medline].

22. Lane-Claypon JE. A further report on cancer of the breast, with special reference to its associated antecedent conditions. Ministry of Health. 1926.

23. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002 Jul 20. 360(9328):187-95. [Medline].

24. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet. 1991 Oct 5. 338(8771):833-8. [Medline].

25. Deng Y, Xu H, Zeng X. Induced abortion and breast cancer: an updated meta-analysis. Medicine (Baltimore). 2018 Jan. 97 (3):e9613. [Medline]. [Full Text].

26. Ventura S, Taffel S, Mosher W, Wilson J, Henshaw S. Trends in pregnancies and pregnancy rates: Estimates for the United States, 1980-92. National Center for Health Statistics. 1995.

27. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997 Jan 9. 336(2):81-5. [Medline].

28. Ye Z, Gao DL, Qin Q, Ray RM, Thomas DB. Breast cancer in relation to induced abortions in a cohort of Chinese women. Br J Cancer. 2002 Oct 21. 87(9):977-81. [Medline]. [Full Text].

29. Henderson KD, Sullivan-Halley J, Reynolds P, et al. Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception. 2008 Jun. 77(6):391-6. [Medline]. [Full Text].

30. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and martial status. Cancer. 1956 Sep-Oct. 9(5):927-34. [Medline].

31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16. 90(18):1371-88. [Medline].

32. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004 Dec 1. 96(23):1751-61. [Medline].

33. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr 17. 94(8):606-16. [Medline].

34. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004 Dec 15. 96(24):1856-65. [Medline].

35. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006 Oct 4. 98(19):1406-15. [Medline].

36. Wang DY, De Stavola BL, Bulbrook RD, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol. 1992 Apr. 21(2):214-21. [Medline].

37. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 2004 Sep 15. 64(18):6814-9. [Medline].

38. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996 Jun 22. 347(9017):1713-27. [Medline].

39. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002 Jun 27. 346(26):2025-32. [Medline].

40. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2002 Nov. 11(11):1375-81. [Medline].

41. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997 Oct 11. 350(9084):1047-59. [Medline].

42. International Agency for Research on Cancer. Combined estrogen-progestogen postmenopausal therapy. In: Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. 2007. Available at http://monographs.iarc.fr/ENG/recentpub/mono91.pdf.

43. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15. 332(24):1589-93. [Medline].

44. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res. 2005 Jan 15. 11(2 Pt 2):909s-17s. [Medline].

45. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17. 288(3):321-33. [Medline].

46. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 Aug 9. 362(9382):419-27. [Medline].

47. Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016 Dec. 59 (4):651-72. [Medline].

48. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006 May 8. 166(9):1027-32. [Medline].

49. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14. 291(14):1701-12. [Medline].

50. Colditz GA. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 2007. 9(4):108. [Medline].

51. Clarke CA, Purdie DM, Glaser SL. Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer. 6:170. [Full Text].

52. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 Feb 5. 360(6):573-87. [Medline].

53. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007 Aug 10. 25(23):3437-9. [Medline].

54. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8. 295(6):629-42. [Medline].

55. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med. 1996 Feb 8. 334(6):356-61. [Medline].

56. Berkey CS, Rockett HR, Willett WC, Colditz GA. Milk, dairy fat, dietary calcium, and weight gain: a longitudinal study of adolescents. Arch Pediatr Adolesc Med. 2005 Jun. 159(6):543-50. [Medline].

57. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst. 2003 Jul 16. 95(14):1079-85. [Medline].

58. World Cancer Research Fund. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: AICR; 2007.

59. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002 Nov 18. 87(11):1234-45. [Medline]. [Full Text].

60. Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst. 2003 Mar 5. 95(5):373-80. [Medline].

61. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer. 2008 Mar. 8(3):205-11. [Medline].

62. Volume 6: Weight control and Physical activity. 2002.

63. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994 Sep 21. 86(18):1403-8. [Medline].

64. Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst. 2008 May 21. 100(10):728-37. [Medline].

65. Hu FB, Sigal RJ, Rich-Edwards JW, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA. 1999 Oct 20. 282(15):1433-9. [Medline].

66. Emaus A, Veierod MB, Furberg AS, et al. Physical activity, heart rate, metabolic profile, and estradiol in premenopausal women. Med Sci Sports Exerc. 2008 Jun. 40(6):1022-30. [Medline].

67. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009 Jan 7. 101(1):48-60. [Medline]. [Full Text].

68. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians. 1997 Nov. 109(6):565-71. [Medline].

69. Guo W, Key TJ, Reeves GK. Adiposity and breast cancer risk in postmenopausal women: results from the UK Biobank prospective cohort. Int J Cancer. 2018 Sep 1. 143 (5):1037-46. [Medline]. [Full Text].

70. Pimentel I, Lohmann AE, Goodwin PJ. Normal weight adiposity and postmenopausal breast cancer risk. JAMA Oncol. 2019 Feb 1. 5 (2):150-1. [Medline].

71. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003 Aug 20. 95(16):1218-26. [Medline].

72. Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Wang K, et al. Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Sci Transl Med. 2015 Aug 19. 7 (301):301ra130. [Medline].

73. Castellino AM. Stiffer Matrix in Fat Tissue May Promote Breast Cancer Risk. Medscape Medical News. Available at http://www.medscape.com/viewarticle/850041#vp_3. August 25, 2015; Accessed: December 18, 2015.

74. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000 Sep 15. 152(6):514-27. [Medline].

75. Vatten LJ, Kvinnsland S. Prospective study of height, body mass index and risk of breast cancer. Acta Oncol. 1992. 31(2):195-200. [Medline].

76. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006 Jul 12. 296(2):193-201. [Medline].

77. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21. 353(3):229-37. [Medline].

78. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007 Jan 18. 356(3):227-36. [Medline].

79. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007 Aug 1. 99(15):1178-87. [Medline].

80. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998 Jun 3. 90(11):814-23. [Medline].

81. Brinton LA, Lubin JH, Murray MC, Colton T, Hoover RN. Mortality rates among augmentation mammoplasty patients: an update. Epidemiology. 2006 Mar. 17(2):162-9. [Medline].

82. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer. 2004 Jan 26. 90(2):294-8. [Medline]. [Full Text].

83. Gammon MD, Santella RM, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev. 2002 Aug. 11(8):677-85. [Medline].

84. Laden F, Collman G, Iwamoto K, et al. 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst. 2001 May 16. 93(10):768-76. [Medline].

85. The health consequences of involuntary exposure to tobacco smoke : a report of the Surgeon General. 2006. Available at http://www.surgeongeneral.gov/library/secondhandsmoke/report/index.html.

86. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr. 58(2):71-96. [Medline].

87. Alim NE, Kiziltan G. Assessment of risk factors of obesity and diet on breast cancer in Ankara, Turkey. Pak J Med Sci. 2016 Nov-Dec. 32 (6):1537-42. [Medline]. [Full Text].

Graham A Colditz, MD, DrPH Niess-Gain Professor, Chief, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; Associate Director, Alvin J Siteman Cancer Center

Graham A Colditz, MD, DrPH is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Epidemiology, American Society for Nutrition, American Society of Preventive Oncology, Society for Epidemiologic Research

Disclosure: Nothing to disclose.

Chandandeep Nagi, MD Associate Professor, Department of Pathology and Immunology, Baylor College of Medicine

Chandandeep Nagi, MD is a member of the following medical societies: American Society of Breast Disease, New York Metropolitan Breast Cancer Group, United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.